# Efficacy, Safety and Pharmacokinetics of Rilzabrutinib in Patients With Warm Autoimmune Hemolytic Anemia (wAIHA)

> **NCT05002777** · PHASE2 · ACTIVE_NOT_RECRUITING · sponsor: **Sanofi** · enrollment: 22 (actual)

## Conditions studied

- Warm Autoimmune Hemolytic Anemia (wAIHA)

## Interventions

- **DRUG:** rilzabrutinib

## Key facts

- **NCT ID:** NCT05002777
- **Lead sponsor:** Sanofi
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** ACTIVE_NOT_RECRUITING
- **Start date:** 2021-12-07
- **Primary completion:** 2024-05-23
- **Final completion:** 2029-12-31
- **Target enrollment:** 22 (ACTUAL)
- **Last updated:** 2025-05-21


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT05002777

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT05002777, "Efficacy, Safety and Pharmacokinetics of Rilzabrutinib in Patients With Warm Autoimmune Hemolytic Anemia (wAIHA)". Retrieved via AI Analytics 2026-06-24 from https://api.ai-analytics.org/clinical/NCT05002777. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*